excerpt: "Pharmacovigilance teams are using virtual assistants to handle adverse event intake triage, safety report coordination, and case tracking workflows—allowing safety scientists to focus on signal detection and medical evaluation." summary: "This article explains how pharmacovigilance departments and drug safety teams leverage virtual assistants for adverse event intake, case tracking, and safety report coordination without replacing medical review functions." metaDescription: "Learn how a pharmacovigilance virtual assistant supports adverse event intake triage, safety case tracking, and expedited report coordination for drug safety teams." keywords: ["pharmacovigilance virtual assistant", "adverse event intake VA", "safety report coordination", "case tracking pharmaceutical", "drug safety VA"] author: "Tricia Guerra"
Pharmacovigilance departments face an unrelenting volume challenge. As post-market safety surveillance requirements expand under ICH E2E and FDA's 21 CFR Part 314.81 obligations, the number of adverse event reports flowing into drug safety teams continues to grow—while the shortage of qualified safety scientists has not improved. The result is a workflow bottleneck where administrative intake and case preparation tasks compete with the medical evaluation and signal detection work that only trained professionals can perform.
According to the Uppsala Monitoring Centre's 2025 Global Pharmacovigilance Landscape Report, the global volume of individual case safety reports (ICSRs) submitted to national regulatory authorities increased by 31% between 2022 and 2024. This surge is driven by expanded spontaneous reporting channels, patient-reported outcomes programs, and increased social media monitoring obligations. Safety teams cannot hire their way out of the problem fast enough.
Virtual assistants trained in pharmacovigilance administrative workflows provide a practical solution.
Adverse Event Intake Triage and Initial Processing
Not every adverse event report that enters a drug safety mailbox is a valid, complete report requiring expedited processing. Many require follow-up to confirm minimum reportability criteria: identifiable reporter, identifiable patient, a suspect product, and an adverse event. Before a safety scientist evaluates a case, significant administrative processing must occur.
A pharmacovigilance virtual assistant manages first-line intake across reporting channels—email, web form submissions, call center case transfers—and performs initial triage: logging each report into the safety database (Argus Safety, ARISg, Oracle Argus, or Veeva Vault Safety), checking for minimum criteria, and flagging incomplete reports that require follow-up. They send acknowledgment communications to reporters and initiate follow-up requests for missing information using standardized templates approved by the safety team.
This intake layer ensures that safety scientists receive structured, pre-processed case files rather than raw reports requiring administrative sorting, materially reducing the time-to-evaluation for every case.
Safety Report Coordination and Expedited Reporting Support
Expedited reporting obligations—15-day reports for serious unexpected adverse drug reactions to the FDA, 7-day reports for fatal or life-threatening unexpected reactions in clinical trials—create intense time pressure on safety teams. The administrative coordination around these reports is significant: narrative preparation, MedDRA coding review, case completeness checks, and submission package assembly all must occur within compressed timeframes.
A VA supports the expedited reporting workflow by preparing case narratives from source documents using approved templates, cross-checking MedDRA coding assignments in the database against the reported terms for review by a qualified safety physician, assembling the E2B submission package, and tracking submission deadlines across active cases in a real-time dashboard. They do not make medical assessments—causality, seriousness, and expectedness determinations stay with licensed safety physicians—but they handle the preparation work that allows physicians to review complete, well-organized case files.
The Drug Information Association's 2024 Global Safety Operations Benchmark found that safety teams with dedicated administrative support for expedited case preparation met submission deadlines at a 96% rate, compared to 82% for teams without such support.
Case Tracking and Periodic Safety Report Preparation
Beyond individual case management, pharmacovigilance teams must maintain visibility across their entire case portfolio—tracking due dates for Periodic Adverse Drug Experience Reports (PADERs), Periodic Benefit-Risk Evaluation Reports (PBRERs), and Development Safety Update Reports (DSURs). Missing a periodic report deadline is a regulatory violation that can trigger warning letters and increased agency scrutiny.
A virtual assistant maintains the periodic report calendar, tracks open cases requiring narrative completion before PBRER lock, coordinates with medical writers for aggregate report preparation, and manages the document workflow in Veeva Vault or the safety document management system. They compile line listings and summary tabulations from the safety database for inclusion in periodic reports and track regulatory authority submissions and acknowledgment confirmations.
This systematic case and report tracking function allows safety operations leads to maintain portfolio oversight without spending hours manually updating status spreadsheets.
Supporting Signal Detection Capacity
The ultimate goal of pharmacovigilance administration is to protect patient safety by ensuring safety signals are detected and evaluated promptly. When safety scientists spend significant time on administrative case processing, signal detection and medical evaluation suffer.
By deploying a virtual assistant to handle structured intake, pre-processing, report coordination, and tracking, drug companies create headroom for their safety scientists to focus on disproportionality analysis, case series evaluation, and benefit-risk assessment—the high-value activities that are impossible to delegate.
To build the administrative support layer your drug safety team needs, learn more about virtual assistants for pharmacovigilance operations.
Sources
- Uppsala Monitoring Centre. 2025 Global Pharmacovigilance Landscape Report. UMC, 2025.
- Drug Information Association. 2024 Global Safety Operations Benchmark. DIA, 2024.
- U.S. Food and Drug Administration. 21 CFR Part 314.81 – Other Post-Marketing Reports. FDA, updated 2024.
- International Council for Harmonisation. ICH E2E Pharmacovigilance Planning Guideline. ICH, updated 2024.